| Mitsubishi Pharma Corporation Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122919 | PHARMACEUTICAL COMPOSITION COMBINING TENATOPRAZOLE AND A HISTAMINE H2-RECEPTOR ANTAGONIST - The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition, which is intended for the treatment of pathologies linked to gastric hyperacidity, comprises a combination of tenatoprazole and one or more histamine H2-receptor antagonists preferably selected from cimetidine, ranitidine, famotidine and nizatidine. The invention is particularly suitable for the treatment of duodenal and gastric ulcers and the symptoms of, and lesions caused by, gastroesophageal reflux. | 05-17-2012 |
| 20110152314 | USE OF TENATOPRAZOLE FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE - The invention relates to a novel therapeutic application of tenatoprazole. Tenatoprazole and the salts thereof can be used in the production of a medicament for the treatment of atypical and esophageal symptoms of gastroesophageal reflux, gastrorrhagia and dyspepsia. | 06-23-2011 |
| 20100048518 | Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent - The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations. | 02-25-2010 |
| 20090239864 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS - A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: | 09-24-2009 |
| 20090220422 | Drug Delivery Material - The present invention provides a drug delivery material, which is a conjugate of 1) a drug-carrying molecular assembly, 2) a linker and 3) a substance that recognizes activated platelet, injury site of blood vessel and/or inflammatory tissue, and capable of efficiently delivering a drug to a desired site, during which the drug under delivery does not affect sites other than a desired site (hence, low possibility of causing side effects), which releases the drug only at the desired site without requiring an external means and allows the drug to exhibit an effect. | 09-03-2009 |
| 20090216016 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF - The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H -pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof. | 08-27-2009 |
| 20090163539 | ENANTIOMER OF TENATOPRAZOLE AND THE USE THEREOF IN THERAPY - This invention relates to optically active substances of tenatoprazole, (+) and (−) -5-methoxy-2-{(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl}-1H-imidazo[4,5-b]pyridine. The compound and pharmaceutical compositions thereof are useful for anti-ulcer agent. | 06-25-2009 |
| 20090124618 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND - A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; represents a C | 05-14-2009 |
| 20090062295 | Pharmaceutical Products - Pharmaceutical products comprising 6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone or a salt thereof, or a hydrate thereof or a solvate thereof as an active ingredient, wherein production of hydrazine is substantially suppressed is provided. | 03-05-2009 |
| 20090048243 | THERAPEUTIC AGENT FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER - A prophylactic and/or therapeutic drug for AD/HD, containing teniloxazine or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, as the active ingredient. | 02-19-2009 |
| 20090005392 | CRYSTAL OF 6-[4-(4-PYRIDYLAMINO) PHENYL]-4,5-DIHYDRO-3(2H-PYRIDAZINONE HYDROCHLORIDE TRIHYDRATE - The present invention provides crystals of 6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride trihydrate useful as a medicament for therapeutic treatment of cardiac failure, and the like; and a pharmaceutical composition comprising said crystals as an active ingredient. | 01-01-2009 |
| 20090004725 | Process For Producing Protein With Reduction of Acidic Sugar Chain and Glycoprotein Produced Thereby - The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus | 01-01-2009 |
| 20080318980 | USE OF 7-(PYRIMIDIN-4 YL)-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONES AS GSK-3BETA INHIBITORS - The invention relates to a imidazo[1,2-a]pyrimidone derivative represented by formula (I) or a salt thereof: | 12-25-2008 |
| 20080269257 | Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives - The invention relates to use of a pyrimidone derivative represented by formula (I) or a salt thereof as therapeutic agents: | 10-30-2008 |
| 20080260741 | Preventive and/or Therapeutic Agent for Cancer - As the results of intensive studies aiming at providing a gene targeting a cancer cell or a cancer tissue, novel nucleotide sequences showing increased expression in a cancer cell or a cancer tissue compared with normal tissues are identified. As the results of the subsequent studies, genes showing increased expression in a cancer cell or a cancer tissue which are useful as a drug discovery target are found out. | 10-23-2008 |
